T2 Biosystms Inc
T2 Biosystems, Inc., an in vitro diagnostics company, develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine. The company also offers T2… Read more
T2 Biosystms Inc (TTOO) - Total Assets
Latest total assets as of September 2024: $18.08 Million USD
Based on the latest financial reports, T2 Biosystms Inc (TTOO) holds total assets worth $18.08 Million USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
T2 Biosystms Inc - Total Assets Trend (2012–2023)
This chart illustrates how T2 Biosystms Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
T2 Biosystms Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
T2 Biosystms Inc's total assets of $18.08 Million consist of 72.4% current assets and 27.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.1% |
| Accounts Receivable | $1.42 Million | 4.1% |
| Inventory | $4.82 Million | 13.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2023)
This chart illustrates how T2 Biosystms Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: T2 Biosystms Inc's current assets represent 72.4% of total assets in 2023, a decrease from 86.2% in 2012.
- Cash Position: Cash and equivalents constituted 45.1% of total assets in 2023, down from 84.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is inventory at 13.9% of total assets.
T2 Biosystms Inc Competitors by Total Assets
Key competitors of T2 Biosystms Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
T2 Biosystms Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - T2 Biosystms Inc generates 0.21x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - T2 Biosystms Inc is currently not profitable relative to its asset base.
T2 Biosystms Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.40 | 0.59 | 0.31 |
| Quick Ratio | 0.24 | 0.52 | 0.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-14.65 Million | $ -22.58 Million | $ -41.68 Million |
T2 Biosystms Inc - Advanced Valuation Insights
This section examines the relationship between T2 Biosystms Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.50 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | 1.2% |
| Total Assets | $34.80 Million |
| Market Capitalization | $498.71K USD |
Valuation Analysis
Below Book Valuation: The market values T2 Biosystms Inc's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: T2 Biosystms Inc's assets grew by 1.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for T2 Biosystms Inc (2012–2023)
The table below shows the annual total assets of T2 Biosystms Inc from 2012 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $34.80 Million | +1.18% |
| 2022-12-31 | $34.39 Million | -43.19% |
| 2021-12-31 | $60.54 Million | -23.44% |
| 2020-12-31 | $79.08 Million | +177.60% |
| 2019-12-31 | $28.49 Million | -55.70% |
| 2018-12-31 | $64.31 Million | +17.22% |
| 2017-12-31 | $54.86 Million | -38.75% |
| 2016-12-31 | $89.57 Million | +3.01% |
| 2015-12-31 | $86.95 Million | +10.31% |
| 2014-12-31 | $78.82 Million | +147.20% |
| 2013-12-31 | $31.89 Million | +178.93% |
| 2012-12-31 | $11.43 Million | -- |